Mechanism of the biological effect of the tumor necrosis factor-аlpha at psoriasis



Cite item

Full Text

Abstract

Among different cytokines, tumor necrosis factor-аlpha (tumor necrosis factor α, TNF-α) plays a special role in psoriatic immunopathogenesis. Data on this cytokine collected for the recent decades made it possible to create a number of biological drugs blocking TNF-α, which are successfully applied in clinical practice for treating medium to severe psoriasis and psoriatic arthritis. This review presents general information about the cytokine structure and its receptor apparatus, regulation mechanisms of TNF-α synthesis and ways of signal transmission as the basis needed to implement the biological effects of cytokine in the development of psoriatic skin affections.

References

  1. Симбирцев А. С. Цитокины: классификация и биологические функции. Цитокины и воспаление. 2004; 3: 2: 16-2.
  2. Carswell E.A., Old L.J., Kassel R.L. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72(9): 3666-3670.
  3. Pennica D., Hayflick J.S., Bringman T.S. et al. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82(18): 6060-6064.
  4. Bodmer J.L., Schneider P., Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002; 27: 19-26.
  5. Mathew S.J., Haubert D., Krönke M., Leptin M. Looking beyond death: a morphogenetic role for the TNF signalling pathway. Journal of Cell Science 2009: 122, 1939-1946.
  6. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl JMed 1996; 334: 1717-1725.
  7. Schottelius A.J.G., Moldawer L.L., Dinarello C.A. et al. Biology of tumor necrosis factor-α implications for psoriasis. Exp Dermatol 2004; 13: 193-222.
  8. Moss M.L., Jin S.L.C., Milla M.E. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor- alpha. Nature 1997; 385: 733-736.
  9. Dean J.L., Wait R., Mahtani K.R. et al. The 3' untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR. Mol Cell Biol 2001 Feb; 21 (3): 721-30.
  10. Chae M.J., Sung H.Y., Kim E.H. et al. Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. Exp Mol Med. 2009 Nov 30; 41 (11): 824-31.
  11. Al-Lamki R.S., Wang J., Skepper J.N. et al. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001; 81(11): 1503-1515.
  12. Tartaglia L. A., Pennica D., Goeddel D. V. Ligand passing: the 75- kd tumor necrosis factor (TNF) receptor recrutits TNF for signaling by the 55 Kd TNF receptor. J Biol Chem 1993: 268 (25): 18542-18548.
  13. Jones S.J., Ledgerwood E.C., Prins J.B. et al. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999; 162 (2): 1042-1048.
  14. Bennett M., Macdonald K., Chan S.W. et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282(5387): 290-293.
  15. Bouwmeester T., Bauch A., Ruffner H. et al. A physical and functional map of the human TNFœ/NF-kB signal transduction pathway. Nat Cell Biol 2004; 6(2): 97-105.
  16. Zhao Y., Conze D.B., Hanover J.A., Ashwell J.D. Tumor necrosis factor receptor 2 signalling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signalling. J Biol Chem 2007; 282(11): 7777-7782.
  17. Baeuerle P.A., Baltimore D. NF-Kappa-B: ten years after. Cell 1996: 87: 13-20.
  18. Wang C.Y., Mayo M.W., Baldwin A.S.J. TNF-and cancer therapy- induced apoptosis: potentiation by inhibition of NF-kappa B. Science 1996; 274 (5288): 784-787.
  19. Pimentel-Muinos F.X., Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999: 11 (6): 783-793.
  20. Edwards C.K. III PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-HusTNF- RI) novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis 1999: 58.
  21. Пальцев М.А., Кветной И.М. Руководство по нейроиммунологии. М.: Медицина, 2006.
  22. Kollias G., Douni E., Kassiotis G., Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999 Jun; 169: 175-94.
  23. Sweiss N.J., Curran J., Baughman R.P. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Clin Dermatol 2007 May-Jun; 25(3): 341-6.
  24. Насонов Е.Л. Фактор некроза опухоли-α - новая мишень для противовоспалительной терапии ревматоидного артрита. Клин. фармакол. терапия 2001; 1: 64-70.
  25. Braun J., Sieper J. Overview of the use of the anti-TNF agent infliхimab in chronic inflammatory diseases. Eхpert Opin Biol Ther 2003; 3: 141-68.
  26. Bradley J.R. TNF-mediated inflammatory disease. J Pathol 2008 Jan; 214(2): 149-60.
  27. Ray J.C., Wang J., Chan J., Kirschner D.E. The timing of TNF and IFN-gamma signaling affects macrophage activation strategies during Mycobacterium tuberculosis infection. J Theor Biol 2008 May 7; 252(1): 24-38. Epub 2008 Jan 20.
  28. Wallis R.S. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007 May; 12(1): 16-21.
  29. Antoniu S.A. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets. 2010 Jan; 14(1): 21-9.
  30. Somoskövi A., Zissel G., Zipfel P.F. et al. Different cytokine patterns correlate with the extension of disease in pulmonary tuberculosis. Eur Cytokine Netw 1999 Jun; 10(2): 135-42.
  31. Fehrenbach H., Zissel G., Goldmann T. et al. Alveolar macrophages are the main source for tumour necrosis factor-аlpha in patients with sarcoidosis. Eur Respir J 2003 Mar; 21(3): 421-8.
  32. Myatt N., Coghill G., Morrison K. et al. Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation. J Clin Pathol 1994 May; 47(5): 423-6.
  33. Hasan Z., Zaidi I., Jamil B. et al. Elevated ex vivo monocyte chemotactic protein-1 (CCL2) in pulmonary as compared with extrapulmonary tuberculosis. BMC Immunol. 2005 Jul 7; 6: 14.
  34. Roach D.R., Bean A.G., Demangel C. et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002 May 1; 168(9): 4620-7.
  35. Newton S.M., Mackie S.L., Martineau A.R. et al. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. Clin Vaccine Immunol 2008 Mar; 15(3): 506-12.
  36. Sasaki M., Namioka Y., Ito T. et al. Role of ICAM-1 in the aggregation and adhesion of human alveolar macrophages in response to TNF-alpha and INF-gamma. Mediators Inflamm. 2001 Dec; 10(6): 309-13.
  37. Pietrzak A.T., Zalewska A., Chodorowska G. et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008 Aug; 394(1-2): 7-21.
  38. Gall J.S., Kalb R.E. Infliximab for the treatment of plaque psoriasis Biologics: Targets & Therapy 2008: 2(1): 115-124.
  39. Watabe D., Kanno H., Yoshida A. et al. Adhesion of peripheral blood mononuclear cells and CD4+ T cells from patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1. Br J Dermatol 2007 Aug; 157(2): 259-65.
  40. Heidenreich R., Röcken M., Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009 Jun; 90(3): 232-48.
  41. Ferran M., Giménez-Arnau A.M., Bellosillo B. et al. Effector function of CLA(+) T lymphocytes on autologous keratinocytes in psoriasis. Actas Dermosifiliogr 2008 Nov; 99(9): 701-7.
  42. Banno T., Gazel A., Blumenberg M. Effects of tumor necrosis factor- alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004 Jul 30; 279(31): 32633-42.
  43. Berger E.M., Gottlieb A.B. Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol 2007 Aug; 7(4): 434-44.
  44. Mimouni D., Anhalt G.J., Kouba D.J., Nousari H.C. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003: 148 (4): 813-816.
  45. Voigtlander C., Luftl M., Schuler G., Hertl M. Infliximab (antitumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon- Wilkinson disease). Arch Dermatol 2001: 137 (12): 1571-1574.
  46. Sullivan T. P., Welsh E., Kerdel F.A. et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003: 149 (5): 1046-1049.
  47. Humeniuk J.M., Gliptis E. Infliximab in the treatment of panniculitis. World Congress Of Dermatology Paris, July 1-5, 2002.
  48. Sacher C., Rubbert A., Konig C. et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002; 46 (1): 113-115.
  49. Kobbe G., Schneider P., Rohr U. et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28 (1): 47-49.
  50. Henter J.I., Karlen J., Calming U. et al. Successful treatment of Langerhans-cell histiocytosis with etanercept. N Engl J Med 2001; 345 (21): 1577-1578.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 ZNAMENSKAYA L.F., YEGOROVA Y.Y., ZITNER S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies